Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMLDAR4)

• Drug Name: TEI-9647 Drug Info
• Synonyms: TEI9647

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 9547692
  ChEBI ID: CHEBI:156177
  CAS Number: CAS 173388-20-0
  TTD Drug ID: DMLDAR4

Molecule-Related Drug Atlas

Drug(s) Targeting Vitamin D3 receptor (VDR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ergocalciferol	DMHO0AR	Hypoparathyroidism	5A50	Approved	[3]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[4]
Calcidiol	DMN4CV5	Hypophosphatemia		Approved	[3]
Doxercalciferol	DM6FG1P	Chronic kidney disease	GB61	Approved	[5]
Calcipotriol	DM03CP7	Psoriasis	EA90	Approved	[6]
Falecalcitrol	DMBI9ZJ	Hyperparathyroidism	5A51	Approved	[7]
Dihydrotachysterol	DMFB97P	Hypocalcemia	5B5K.1	Approved	[8]
Cholecalciferol	DMGU74E	Adult acute monocytic leukemia		Approved	[9]
Paricalcitol	DMYBV3G	Hyperparathyroidism	5A51	Approved	[10]
Seocalcitol	DMKL9QO	Rickets	5B57	Phase 3	[11]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Vitamin D3 receptor (VDR)	TTK59TV	VDR_HUMAN	Antagonist	[2]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2788).
• [2] Further synthetic and biological studies on vitamin D hormone antagonists based on C24-alkylation and C2alpha-functionalization of 25-dehydro-1alpha-hydroxyvitamin D(3)-26,23-lactones. J Med Chem. 2006 Nov 30;49(24):7063-75.
• [3] Vitamin D in health and disease. Clin J Am Soc Nephrol. 2008 Sep;3(5):1535-41.
• [4] Kaposi sarcoma is a therapeutic target for vitamin D(3) receptor agonist. Blood. 2000 Nov 1;96(9):3188-94.
• [5] Emerging drugs for psoriasis. Expert Opin Emerg Drugs. 2009 Mar;14(1):145-63.
• [6] Cellular and molecular mechanisms involved in the action of vitamin D analogs targeting vitiligo depigmentation. Curr Drug Targets. 2008 Apr;9(4):345-59.
• [7] Synthesis and biological evaluations of A-ring isomers of 26,26,26,27,27,27-hexafluoro-1,25-dihydroxyvitamin D3. Bioorg Med Chem. 2000 Aug;8(8):2157-66.
• [8] In vivo metabolism of the vitamin D analog, dihydrotachysterol. Evidence for formation of 1 alpha,25- and 1 beta,25-dihydroxy-dihydrotachysterol metabolites and studies of their biological activity. J Biol Chem. 1993 Jan 5;268(1):282-92.
• [9] [Vitamin D2 or vitamin D3]. Rev Med Interne. 2008 Oct;29(10):815-20.
• [10] New acquisitions in therapy of secondary hyperparathyroidism in chronic kidney disease and peritoneal dialysis patients: role of vitamin D receptor... Contrib Nephrol. 2009;163:219-226.
• [11] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.